Home » GUIDANT UPDATED TO 'BUY'
GUIDANT UPDATED TO 'BUY'
Analyst Glenn Novarro of Banc of America Securities upgrades Guidant from "neutral"
to "buy," while reducing his estimates for the company. The target
price has been reduced from $69 to $66.
Newratings
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May